Research Collaborations, In-licenses and Acquisitions
Targeting the continual creation of new drugs, we are promoting research collaborations with various parties inside and outside Japan, including universities, research institutions and venture companies possessing innovative technologies.
Toward positive strategic Investment on Alliance and Licensing
We are collecting information in various forms including investment into "DEFTA Healthcare Technologies, L.P." in addition to a bio-venture fund "Apposite Healthcare Fund, L.P." and "Remiges BioPharma Fund, L.P."
|Investment destination||Investment fields|
|Apposite Healthcare Fund, L.P.||Life sciences, healthcare services|
|Remiges BioPharma Fund, L.P.||Pharmaceuticals research and
development and other life sciences
|DEFTA Healthcare Technologies, L.P.||Leading-edge medical treatments and
regenerative medicine, next-generation
medical devices, and healthcare IoT/ICT
Major External Collaboration
Kyoto University : Project for drug discovery research focusing on the regulatory mechanisms of cell - cell interactions in tumor microenvironment (DSK Project)
Kyoto University and Sumitomo Dainippon Pharma unite their expertise (for instance, the ample experience and knowledge from basic and clinical researches in Kyoto University and the knowledge and resources in drug R&D and regulatory affairs, and management skills in Sumitomo Dainippon Pharma) to establish a research center where selected young scientists are supported to establish their own research units and to pursue their original and promising ideas that will eventually lead to the development of new drugs, materials, or concepts useful for cancer prevention, diagnosis, or therapy.
The Kitasato Institute: Joint Drug Discovery Research for AMR "KS-Project"
Sumitomo Dainippon Pharma is conducting joint research with a drug discovery group led by Dr. Satoshi Omura, Distinguished Emeritus Professor of Kitasato University and the 2015 laureate of the Nobel Prize in Physiology or Medicine, with the aim of discovering new drugs against infections caused by bacteria with antimicrobial resistance (AMR). This joint R&D initiative was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program.
The Center for iPS Cell Research and Application (CiRA)
- This joint research collaboration between industry and academia, focusing on a rare intractable disease caused by genetic mutation, aims to use induced pluripotent stem cells (iPS cells) to identify the pathognomonic mechanism of the disease, identify the most disease-specific target molecule from various pathological changes of signal transduction, and screen specific inhibitors against the signal pathway. As a result, the aim is to create an epoch-making treatment to suppress detrimental conditions in patients.
- CiRA and Sumitomo Dainippon Pharma are conducting joint research and development to establish the world's first Parkinson's disease treatment using allogeneic iPS cell-derived dopaminergic neural progenitor cells.
The Center for iPS Cell Research and Application (CiRA) and Hitachi Ltd.
CiRA, Hitachi Ltd., and Sumitomo Dainippon Pharma are jointly developing the base technology and evaluation methods to establish a production process for dopaminergic neural progenitor cells. This will be used to develop the world's first Parkinson's disease treatment using allogeneic iPS cell-derived dopaminergic neural progenitor cells. These endeavors are part of the "Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine" commissioned by The Japan Agency for Medical Research and Development (AMED).
Healios K.K. and Sumitomo Dainippon Pharma are conducting joint development in Japan of iPS cell-derived retinal pigment epithelial cells (RPE cells) for the treatment of age-related macular degeneration and other eye diseases.
Keio University and National Hospital Organization Osaka National Hospital
Under the Research Center Network for Realization of Regenerative Medicine, a joint initiative between government, industry and academia, Sumitomo Dainippon Pharma, together with the National Hospital Organization Osaka National Hospital, is taking part as a contributing organization in the Keio University (Professor Hideyuki Okano) project on "Regenerative medicine for spinal cord injury and stroke using iPS cell-derived neural precursor cells." The goal of the project is to develop a treatment for the transplantation of iPS cell-derived neural precursor cells for spinal cord injury.
In basic research, Sumitomo Chemical Co., Ltd. in partnership with RIKEN has succeeded in generating a three-dimensional retina from human embryonic stem cells, a world first. Following on from this, Sumitomo Dainippon Pharma aims to create a treatment available using an allogeneic iPS cell-derived three-dimensional retina.
Carna Biosciences, Inc.
Carna Bioscience and Sumitomo Dainippon Pharma are conducting joint research with a view toward discovering novel kinase inhibitors indicated for psychiatric and neurological disorders by combining accumulated Carna Biosciences's know-how on kinase inhibitor discovery with Sumitomo Dainippon Pharma's know-how on drug discovery research in the area of neuroscience.
Promoting Strategic Investment to Acquire Companies and In-license Development Products
From the viewpoint of expanding the development pipeline, we are actively promoting strategic investment to acquire companies and in-license development products. In relation to in-licensing, we consider a wide variety of late development stage products as a priority with a focus on Psychiatry & Neurology, oncology and specialty areas.
Major recent acquisitions
(Development products are the situation at the time of acquisitions)
|Company acquired||Date acquired||Major development products|
|Product code||Development stage||Development location||Category|
|Tolero Pharmaceutical, Inc. (U.S.)||January 2017||alvocidib (Generic name)||Phase 2||U.S./Canada||Anticancer drug|
|TP-0903||Phase 1||U.S.||Anticancer drug|
|Cynapsus Therapeutics Inc. (Canada)
(currently Sunovion CNS Development Canada ULC)
|October 2016||APL-130277||Phase 3||U.S.||Therapeutic agent for Parkinson's disease|
Major recent in-licensed products
(Development stage etc. are the situation at the time of in-licenses)
|imeglimin||type 2 diabetes||Poxel SA
|October 2017||completed Phase 2||Japan|
|SanBio, Inc. (U.S.)||September
ceuticals, Inc.) (U.S.)